OK, Eagle8, no worries brother. I did not mean to pick on you I am just tired of people that are not invested in this company howling around about irrelevant factors. The plan is to have the trials paid for by partnerships and grants. So far most of the trials have been paid for by grants and outside sources doing research. Anavex uses it's money wisely and frugally to avoid debt and secondary securities sales. So no debt or securities sold will be sold to finance these trials. That has been the plan and it is the plan going forward. This is great benefit to us as shareholders. One does not have to be an accountant to recognize that Anavex has an excellent balance sheet for a clinical stage company. Good Luck
News 
Market Data 
Discover 
